drugset / Trial / NCT00606593

Almorexant (ACT-078573) in Elderly Subjects With Chronic Primary Insomnia

NCT00606593

Phase 2 Completed 112 enrolled Midnight Pharma, LLC
RandomizedCrossoverQuadruple-blindTreatment

Summary

A 2-night polysomnography / 5-way cross-over study to evaluate the effect, safety and tolerability of oral administration of almorexant (ACT 078573) in elderly subjects with primary insomnia.

Timeline

Start
2007-12
Primary completion
2008-04
Completion
2008-05

Drugs

EvaluationDrugModalityDoseRoute
Subject almorexant Small molecule 25 mg Oral
Subject almorexant Small molecule 50 mg Oral
Subject almorexant Small molecule 100 mg Oral
Subject almorexant Small molecule 200 mg Oral

Indications